In less than a year, Umoja Biopharma has made noise with its next-gen CAR-T immunotherapies, a few splashy hires and $263 million in financing. Now the Seattle-based startup is undergoing the next ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results